{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Alcicek S"],"funding":["Mildred-Scheel Career Center of the German Cancer Aid","Discovery & Development Project Grant of the LOEWE Frankfurt Cancer Institute"],"pubmed_abstract":["<h4>Background</h4>Glutamate and glutamine are critical metabolites in gliomas, each serving distinct roles in tumor biology. Separate quantification of these metabolites using in vivo MR spectroscopy (MRS) at clinical field strengths (≤ 3T) is hindered by their molecular similarity, resulting in overlapping, hence indistinguishable, spectral peaks.<h4>Purpose</h4>To develop an MRS imaging (MRSI) protocol to map glutamate and glutamine separately at 3T within clinically feasible time, using J-modulation to enhance spectral differentiation, demonstrate its reliability/reproducibility, and quantify the metabolites in glioma subregions.<h4>Study type</h4>Prospective.<h4>Population</h4>Phantoms, 5 healthy subjects, and 30 patients with suspected glioma. IDH wild-type glioblastoma cases were ev"],"journal":["Journal of magnetic resonance imaging : JMRI"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12335340"],"repository":["biostudies-literature"],"pubmed_title":["Optimized Long-TE &lt;sup&gt;1&lt;/sup&gt;H sLASER MR Spectroscopic Imaging at 3T for Separate Quantification of Glutamate and Glutamine in Glioma."],"pmcid":["PMC12335340"],"pubmed_authors":["Ronellenfitsch MW","Weber KJ","Thomas DC","Manzhurtsev A","Pilatus U","Wenger KJ","Steinbach JP","Hattingen E","Forster MT","Alcicek S","Prinz V"],"additional_accession":[]},"is_claimable":false,"name":"Optimized Long-TE &lt;sup&gt;1&lt;/sup&gt;H sLASER MR Spectroscopic Imaging at 3T for Separate Quantification of Glutamate and Glutamine in Glioma.","description":"<h4>Background</h4>Glutamate and glutamine are critical metabolites in gliomas, each serving distinct roles in tumor biology. Separate quantification of these metabolites using in vivo MR spectroscopy (MRS) at clinical field strengths (≤ 3T) is hindered by their molecular similarity, resulting in overlapping, hence indistinguishable, spectral peaks.<h4>Purpose</h4>To develop an MRS imaging (MRSI) protocol to map glutamate and glutamine separately at 3T within clinically feasible time, using J-modulation to enhance spectral differentiation, demonstrate its reliability/reproducibility, and quantify the metabolites in glioma subregions.<h4>Study type</h4>Prospective.<h4>Population</h4>Phantoms, 5 healthy subjects, and 30 patients with suspected glioma. IDH wild-type glioblastoma cases were ev","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-05-01T08:47:09.933Z","creation":"2026-04-07T16:45:27.427Z"},"accession":"S-EPMC12335340","cross_references":{"pubmed":["40197808"],"doi":["10.1002/jmri.29787"]}}